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One test for all: whole exome sequencing 
significantly improves the diagnostic 
yield in growth retarded patients referred 
for molecular testing for Silver–Russell 
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Abstract 
Background: Silver-Russell syndrome (SRS) is an imprinting disorder which is characterised by severe primordial 
growth retardation, relative macrocephaly and a typical facial gestalt. The clinical heterogeneity of SRS is reflected by 
a broad spectrum of molecular changes with hypomethylation in 11p15 and maternal uniparental disomy of chromo-
some 7 (upd(7)mat) as the most frequent findings. Monogenetic causes are rare, but a clinical overlap with numerous 
other disorders has been reported. However, a comprehensive overview on the contribution of mutations in dif-
ferential diagnostic genes to phenotypes reminiscent to SRS is missing due to the lack of appropriate tests. With the 
implementation of next generation sequencing (NGS) tools this limitation can now be circumvented.
Main body: We analysed 75 patients referred for molecular testing for SRS by a NGS-based multigene panel, whole 
exome sequencing (WES), and trio-based WES. In 21/75 patients a disease-causing variant could be identified among 
them variants in known SRS genes (IGF2, PLAG1, HMGA2). Several patients carried variants in genes which have not yet 
been considered as differential diagnoses of SRS.
Conclusions: WES approaches significantly increase the diagnostic yield in patients referred for SRS testing. Several 
of the identified monogenetic disorders have a major impact on clinical management and genetic counseling.
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Background
Growth retardation is a common condition and often 
manifests during pregnancy. Though several non-genetic 
factors have been identified, a significant number of 
patients with growth retardation carry genetic altera-
tions. Severe intrauterine and postnatal growth fail-
ure is a typical feature of Silver-Russell syndrome (SRS, 
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OMIM#180860), a congenital disorder which is addition-
ally characterised by relative macrocephaly (head cir-
cumference at birth ≥ 1.5 SDS above birth weight and/
or length SDS), asymmetry, a typical triangular face with 
a prominent forehead, and feeding difficulties. However, 
due to the low specificity and heterogeneity of features 
the clinical diagnosis of SRS is difficult, and therefore the 
Netchine–Harbison clinical scoring system (NH-CSS) 
has been suggested to standardise the subjective clinical 
diagnosis [1, 2] (see Additional file 1:  Table 1). Addition-
ally, the clinical diagnosis is complicated by the lack of 
specificity of several symptoms and the phenotypic over-
lap with other (growth retardation) disorders.
The clinical heterogeneity of SRS is reflected by a broad 
spectrum of molecular disturbances. With nearly 40%, 
the major finding in patients with the typical SRS phe-
notype is loss of methylation (LOM) of the imprinting 
centre region 1 (IC1, H19/IGF2:IG-DMR) in 11p15.5 (for 
review: [2]). Up to 10% of SRS patients exhibit a maternal 
uniparental disomy of chromosome 7 (upd(7)mat), and a 
relevant number of patients carry alterations of chromo-
some 14q32 which are typically associated with Temple 
syndrome (TS14, OMIM#616222). In fact, TS14 patients 
show a clinical overlap with SRS, but both carriers of 
upd(7)mat and 14q32 alterations exhibit a less typical 
SRS phenotype compared to patients with an IC1-LOM 
[1, 3]. Nevertheless, even in the IC1-LOM group the clin-
ical picture is variable. Additional molecular alterations 
in SRS comprise less common genetic variants, i.e. UPDs 
of chromosome 20, diverse submicroscopic deletions and 
duplications (copy number variants, CNV) [4], and path-
ogenic variants in single genes. These molecular changes 
are either associated with typical SRS phenotypes (e.g. 
microdeletions in 12q14, pathogenic variants in IGF2, 
CDKN1C, PLAG1, HMGA2) [4–6],  or with differential 
diagnoses of SRS (see [2]).
Both clinical and molecular heterogeneity make the 
decision on the diagnostic procedure in SRS challeng-
ing. To address this issue, a stepwise testing procedure 
has been consented, starting with IC1 LOM analysis as 
the first step, followed by testing for upd(7)mat, 14q32 
and CNVs [2]. However, the subsequent testing strategies 
have not yet been defined, and the knowledge on further 
SRS (spectrum) causing genes or associated genomic 
variants are mainly based on single reports as systematic 
screening studies aiming on the contribution of mono-
genic variants to the molecular SRS spectrum are still 
missing. With the implementation of next generation 
sequencing (NGS)-based assays in genetic testing, com-
prehensive approaches to address a broad spectrum of 
monogenetic diseases have become available. Our group 
has recently demonstrated the suitability of targeted 
multigene NGS panels to increase the diagnostic yield in 
patients with SRS features [7], and first data from whole 
exome sequencing were promising as well [8].
We now report on the results of a systematic WES 
approach in a cohort of growth-retarded patients referred 
for SRS diagnostics, and compare the results with tar-
geted multigene NGS panel data in the same cohort.
Study cohort
The total cohort consisted of 75 patients with SRS but 
negatively tested for the typical molecular SRS findings 
(IC1 LOM, upd(7)mat, 14q32 alterations). WES data 
were available from 60 patients, the remaining 15 data-
sets were taken from a targeted NGS approach published 
recently [7]. In addition to 14 patients not previously ana-
lysed by NGS approaches, the cohort included patients 
already analysed with a targeted NGS approach (n = 47) 
[7] and from a recent pilot WES study (n = 45) [8], which 
also partially overlaps (n = 31).
In 22 of these patients, the parents were also analysed 
by WES (trio-based WES).
To determine the detection rate by the three strate-
gies—targeted NGS, index-based WES and trio-based 
WES—datasets from all 75 patients were included.
Clinical scoring was leaned on the NH-CSS [1, 2]. The 
study was approved by the ethical committee of the Med-
ical Faculty of the RWTH Aachen (EK303-18).
Materials and methods
The first step molecular diagnostic testing in all patients 
comprised analyses of IC1 LOM and upd(7)mat analy-
sis by methylation-sensitive multiplex ligation-depend-
ent probe amplification assays, which also covers 14q32 
alterations (MS-MLPA)(ME030, ME032; MRC Holland, 
Amsterdam/NL). This initial screening was conducted 
by the authors or by external laboratories. After exclu-
sion of these (epi)mutations, all samples were screened 
for upd(20)mat, upd(16)mat and submicroscopic copy 
number variations (> 50 kb) by microsatellite typing, MS-
MLPA (ME034), MS single nucleotide primer extension 
and SNP array analysis (deletions/duplications > 50  kb, 
CytoScan® HD Array (Affymetrix, Santa Clara/CA, 
USA)). Nearly all patients were negatively tested with one 
exception with an OBSL1 microdeletion (patient 7).
For whole exome sequencing of the index patients 
and their parents DNA samples isolated from periph-
eral blood were enriched using the Nextera Rapid Cap-
ture Exome (v.1.2) (Illumina, San Diego, CA, USA). The 
enriched libraries were sequenced on a NextSeq500 
Sequencer with 2 × 75 cycles on a high-output flow cell. 
Fastq file generation and adapter trimming was per-
formed using bcl2fastq2 (Illumina, San Diego, CA, USA). 
The automated SeqMule pipeline (v1.2.6) was used for 
fastq quality assessment (FastQC, v.0.11.2), alignment 
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(BWA-MEM, v.0.7.8-r455), duplicate removal (SAM-
tools, rmdup, v.0.1.19–44,428  cd), Indel Realignment 
(GATKLite realign; v.2.3–9)) and variant calling. Three 
different variant callers were used (GATKLite, (Uni-
fiedGenotyper version: 2.3–9), SAMtools (mpileup; 
v.0.1.19–44428  cd), FreeBayes (v.0.9.14–14-gb00b735)) 
for variant detection, and variants shared by at least 
two out of three variant callers were considered for fur-
ther analysis. Annotation and bioinformatic prioritiza-
tion of variants was performed using KGGSeq (v1.0, 20/
Jun./2018). Variants with a minor allele frequency (MAF) 
higher than 0.75% in public databases (i.e. gnomAD, 
EXAC, 1000 GP, ESP) and synonymous variants were 
excluded. Sequencing variants were classified according 
to the ACMG criteria [9]. Variants identified as patho-
genic or likely pathogenic were confirmed by Sanger 
sequencing on an ABI3500 platform (Applied Biosys-
tems, Foster City, CA, USA) and segregation analysis in 
the family was performed if possible.
WES data were analyzed for variants in the genes 
included in the panel approach (for the list of genes see 
Additional file 2:   Table 2 [7]). The achieved WES data 
from our cohort were filtered for pathogenic variants in 
all genes listed in OMIM. In 22 patients, parental DNA 
samples could be used for trio WES analysis. The com-
parison of detection rates of the three strategies was then 
restricted to the subcohort from [7] as these patients 
were analyzed by all three approaches.
Results
In a cohort of 75 patients referred for SRS testing, NGS 
data were analysed to identify the disease-causing genetic 
alterations. WES data were available for 59 patients: For 
14 patients these datasets were newly generated, for the 
remaining 45 cases data from a recent study were com-
piled [8]. In 16 patients, only panel-based NGS data were 
considered. In 22 out of the 59 patients analysed by WES, 
parental samples were available for trio-based analysis.
In the total cohort, pathogenic variants explaining the 
growth retardation phenotypes could be detected in 21 
cases (28.0%), six of them had been published recently [7, 
8]. The molecular and clinical data of the newly identified 
15 patients are listed in Table 1 and a short description is 
given in the Additional file 3:    Table 3.
For comparison of the diagnostic yield of the differ-
ent approaches, detection rates of the WES (index only) 
and WES trio strategies were restricted to those 47 
patients originally analysed with a targeted multigene 
panel by Meyer et al. [7] (Fig. 1). In 31 negatively tested 
samples from this subcohort, WES was performed, and 
allowed the identification of four genetic variants (4 out 
of 31 patients: 12.9%), affecting the genes ORC1, FDG1, 
KMTC2, and PTPN11. Trio analysis in 16 families out of 
this group revealed four additional pathogenic variants 
(4 out of 16 families: 25.0%) in the FANCA, MBTPS1, 
CNOT3, and NF1 genes. In total, a cumulative detection 
rate of more than 40% could be achieved by this step-
wise procedure.
The correlation of the clinical data with the genetic 
findings confirmed that patients carrying mutations in 
genes associated with SRS generally showed a higher NH-
CSS score (PLAG1 in patient 1, IGF2 in patient 5a and 
her sister 5b, HMGA2 in patient 6). However, despite a 
scoring of at least 4 out of 6 criteria, none of them exhib-
ited both key features, relative macrocephaly at birth and 
protruding forehead. Whereas protruding forehead was 
present in the majority of patients, relative macrocephaly 
at birth was observed only in the patient with a homozy-
gous MBTPS1 variant (patient 8). In general, intrauterine 
and postnatal growth retardation associated with a trian-
gular face were the major reasons for referral to diagnos-
tic testing and led to the clinical diagnosis of SRS, though 
several patients did not fulfil the NH-CSS criteria.
Though clinical scoring was not applicable in all cases, 
the correlation between clinical scoring and the test-
ing strategies showed that pathogenic variants in several 
patients with a positive NH-CSS score could be identified 
only by (Trio) WES but not by the panel-based approach 
(Fig. 1).
Discussion
The identification of molecular causes of growth retarda-
tion is hampered by the large number of genetic factors 
contributing to growth. Even in SRS as a recognizable 
phenotype the spectrum of pathogenic variants is broad, 
and only in up to 60% of patients with the typical SRS 
features the disease-specific molecular alterations (IC1-
LOM, upd(7)mat, 14q32 alterations) can be detected 
[10]. Thus, a significant number of patients remain with-
out a molecular confirmation of their diagnosis, and only 
some of them might be explained by mosaicism of the 
IC1-LOM in 11p15.5 which escapes detection in case of 
an extremely discrepant distribution in the body [11]. In 
single families pathogenic variants in genes localized in 
11p15.5 (IGF2, CDKN1C) or members of the HMGA2-
PLAG1-IGF2 pathway have been identified [12–14].
The clinical diagnosis of SRS is additionally hampered 
by the lack of specificity of its major symptoms, and the 
overlap with other congenital disorders. As array based 
studies show, several patients with SRS features carry 
pathogenic submicroscopic copy number variations 
associated with differential diagnoses of SRS (CNVs) 
[4]. Accordingly, small variants in differential diagnostic 
genes have also been described in SRS patients [2, 7]. To 
encompass this broad range of putative disease-causing 
genes, NGS based strategies are a valuable tool as they 
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have the potential to cover all genes and genomic vari-
ants which might contribute to a specific phenotype. First 
studies have already confirmed the power of targeted and 
whole exome NGS approaches to increase the diagnostic 
yield in growth retarded patients [7, 8, 15, 16].
In our cohort of patients referred for SRS testing, we 
now substantiate the need of NGS-based assays in the 
molecular diagnostic workup in this heterogeneous 
cohort, and in agreement with findings from other het-
erogeneous disorders we show that the application of 
WES significantly improves the detection rate (21.41% 
versus 8.5% in the cohort analysed by Meyer et al. [7]) for 
comparable hands-on time and costs. As our data show, a 
further increase can be achieved by trio analysis, both in 
patients fulfilling the clinical SRS criteria according to the 
NH-CSS score as well as in clinically unselected patients 
referred for SRS testing (Fig. 1).
Our molecular findings reflect the molecular hetero-
geneity in patients referred for SRS testing as we could 
identify pathogenic variants in (a) already known SRS 
genes, in (b) genes associated with differential diagnoses 
of SRS, in (c) genes causing phenotypes overlapping with 
SRS.
SRS genes (Table 1a)
Up to now, pathogenic variants which might cause the 
characteristic SRS phenotype have been identified in 
four genes. The imprinted genes CDKN1C and IGF2 
are localized in 11p15.5, and HMGA2 and PLAG1 inter-
act with IGF2 [14]. In our cohort, we identified patho-
genic variants in three of them. In two sibs affected by 
SRS (patients 2a/b), an IGF2 variant was inherited from 
the healthy father which corresponds to the paternal 
expression of the gene. In contrast to IGF2, the mode 
of inheritance of variants in HMGA2 and PLAG1 is not 
influenced by the sex of the parent contributing the 
affected allele as these genes are not imprinted. To the 
best of our knowledge, the frameshift variant in patient 1 
is the third PLAG1 variant reported in the literature [14], 
and its de-novo occurrence supports the autosomal-
dominant mode of inheritance. The HMGA2 variants 
from our cohort (patients 3, 4a/b) have been reported 
recently [17]. Clinically, the patients show growth retar-
dation and SRS features, and the NH-CSS scoring ranges 
between 4 and 5 parameters. Protruding forehead as one 
of the two key features of SRS was present in all of them, 
but relative macrocephaly as the second main sign was 
absent. For HMGA2, the clinical findings correspond to 
cases recently overviewed by Leszenski et al. [18].
Genes associated with already identified differential 
diagnoses of SRS (Table 1b)
As it could be expected from previous reports [2], sev-











Total detection rate Detection rate in case NH-
CSS was applicable
Detection rate in case NH-
CSS was positive
Detection rate in case NH-
CSS was not applicable
Panel Index-based WES Trio-based WES
Fig. 1 Detection rates of different NGS approaches in the cohort of patients referred for SRS testing, and discrimination of the diagnostic yields 
between patients for whom the clinical score was applicable, and NH-CSS positive cases (NH-CSS ≥ 4 items) and patients without sufficient clinical 
data (for number see Additional file   4). Comparison of the detection rates between the multigene panel approach [7] with those obtained by 
WES approaches revealed a significant increase in patients with a positive NH-CSS score as we well as in patients for whom clinical scoring was not 
possible
Page 8 of 10Meyer et al. Orphanet J Rare Dis           (2021) 16:42 
our cohort, including a disturbance of IGF1R (patient 5), 
Meier-Gorlin syndrome 1 (MGS1; ORC1, patient 6), and 
3 M syndrome 2 (OBSL1, patient 7). In all these patients, 
severe postnatal (and intrauterine) growth retardation 
was reported, and this feature was the reason for inclu-
sion in the study. However, microcephaly is the clinical 
feature which allows the discrimination between SRS and 
the majority of its differential diagnosis, in our cohort 
IGF1R disturbances and MGS1 [19, 20]. Nevertheless, 
it should be noted that the patient with the OBSL1 vari-
ant exhibited relative macrocephaly at least at the age of 
2  years 5  months, and our case confirms that 3-M syn-
drome is a relevant differential diagnosis of SRS [21].
Genes causing phenotypes overlapping with SRS (Table 1c)
The results from exome wide screening for pathogenic 
variants in our cohort confirms that there is a broad 
clinical overlap between SRS and other congenital dis-
orders. Therefore, the restriction to a selection of genes 
with higher degree of clinical concordance should be dis-
cussed, as the application of targeted panel will miss the 
detection of relevant mutations, in particular in tumour 
predisposition genes.
The only patient with relative macrocephaly at birth 
and positive NH-CSS scoring is homozygous for a 
MBTPS1 variant (patient 8). Interestingly, the same vari-
ant has already been reported in another growth retarded 
patient for whom the diagnosis of SRS was also discussed 
[22]. Thus, we suggest to add MBTPS1-associated disor-
ders to the list of differential diagnosis of SRS.
In two patients (patients 9 and 10), we identified path-
ogenic variants in tumour predisposition syndromes. 
These growth retarded patients were reported to show 
the typical facial gestalt of SRS, and were born small for 
gestational age. FANCA-associated Fanconi anemia has 
not yet been reported as differential diagnosis of SRS, 
but the clinical overlap is obvious. In patient 9 from 
this report, Fanconi anemia was diagnosed at the age of 
11 years 9 months. In contrast, patient 10 with a patho-
genic NF1 variant only showed slight symptoms of neu-
rofibromatosis type 1 but symptoms consistent with SRS. 
The variant of our patient has already been reported in an 
NF1 patient in combination with short stature [23].
In five further patients (patients 11–15), pathogenic 
variants compatible with their clinical features could be 
identified. None of the associated disorders has already 
been suggested as differential diagnosis of SRS, and clini-
cal scoring shows that none of these individuals had the 
typical SRS picture. All were ascertained due to growth 
retardation and a facial gestalt described as “triangular”.
The results from our study cohort confirm the strengths 
of NGS-based strategies to decipher the molecular basis of 
congenital disorders (for review: [24]), and the comparison 
between them also demonstrates their chances and chal-
lenges. Whereas the increase of the detection rate by WES 
in comparison to the targeted multigene panel approach 
does not need further explanation, the reason for an addi-
tional chance to detect disease-causing variants by trio 
analysis needs some further comments:
Trio WES includes additional information and allows 
phasing of the detected variants. Thereby it enables the 
detection of true compound-heterozygous and de novo 
variants. Furthermore, it helps to determine if a vari-
ant in an imprinted gene affects the expressed or the 
silenced copy. The estimation of pathogenicity of variants 
in imprinted genes requires this further information on 
inheritance and imprinting status. Even a variant with a 
severe functional impact might be without clinical rel-
evance when the affected copy of the imprinted gene is 
silenced (i.e. maternal IGF2 variants).
The detection of a de novo occurrence of a variant can 
decisively influence the assessment of its pathogenicity. 
As stated in the ACMG guidelines, de novo occurrence 
represents a strong criteria for pathogenicity [9]. Trio 
WES allows the time-saving determination of the path-
ogenicity of variants of uncertain significance, and the 
confirmation of compound heterozygosity and of parent-
hood which is a key criteria for classification [9].
In fact, our study has several limitations. It is based 
on a cohort of patients referred for SRS diagnostic, but 
with only limited clinical information (Additional file  3: 
Table 3). The study population therefore includes a con-
siderable number of patients who do not fulfill clinical 
criteria of SRS [1]. However, this situation reflects the 
routine diagnostic workup of a clinically heterogeneous 
group of patients, for which clinical data are rarely pro-
vided. As a consequence, this dataset does not reflect the 
relative contribution of different monogenic causes to the 
SRS phenotype, but it allows to broaden the spectrum of 
disorders with a clinical overlap with SRS. Interestingly, 
even three out of four patients with typical SRS alterations 
(i.e. PLAG1, IGF2, HMGA2) would not be diagnosed as 
“clinical SRS” according to diagnostic criteria consented 
recently [2]. The identification of two patients with tumor 
predisposition variants (FANCA, NF1) again confirms 
that the strategy of a broad testing is needed in patients 
diagnosed with SRS. In these situations, the testing result 
provides the basis for a more precise therapeutic manage-
ment, which includes the decision on or against growth 
hormone treatment and tumor monitoring.
The comparison between the different NGS strate-
gies is also difficult as the targeted multigene panel used 
in this study does not reflect the current knowledge on 
genes contributing to the SRS phenotype. In fact, the use 
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of panel based NGS assays avoids the detection of unso-
licited findings, but it is only of limited value for het-
erogeneous disorders like SRS. As we could show, more 
than half of the pathogenic variants would be missed by 
application of a targeted gene panel because several of 
the identified genes were not included in the multigene 
panel assay. Furthermore, a multigene panel reflects the 
knowledge at the time of the panel design. As the vari-
ant in the SRS gene PLAG1 shows, it was missed in our 
targeted NGS approach as at the time of the panel design 
[7] PLAG1 had not yet been identified as SRS gene. A tar-
geted multigene panel can certainly be upgraded, and fur-
ther genes can be added to a new panel version or spiked 
in into an existing enrichment kit, but samples analysed 
by a previous version cannot be reanalysed.
We therefore suggest WES as a general wet-lab enrich-
ment strategy. To avoid incidental findings and a huge 
number of variants of unknown significance, the WES 
data might be filtered by a step-wise virtual multigene 
panel. If new disease-causing genes are identified, these 
data can then be reanalysed without generation of new 
NGS data. In addition, the WES data can be analysed 
repeatedly to identify pathogenic variants in differential 
diagnosis genes which are not in the focus and would 
be missed by multigene panels. In case WES in a sin-
gle case is negative, a trio analysis might be considered. 
Additionally, the upcoming implementation of whole 
genome sequencing (WGS) in molecular genetic testing 
trials will show whether the detection rates can be fur-
ther increased.
Conclusions
Our data confirm that WES is a suitable tool to achieve 
a significant increase of the diagnostic yield in patients 
referred for SRS testing. The data further contribute to 
the heterogeneous molecular spectrum of SRS and clini-
cally overlapping disorders, the identified cases demon-
strate the need for precise molecular confirmation as the 
basis for precision medicine. The foreseeable diagnostic 
implementation of WGS, long read sequencing (third 
generation sequencing) in combination with transcrip-
tomics will allow the identification of all molecular alter-
ations in one analysis.
Databases
ClinVar: https ://www.ncbi.nlm.nih.gov/clinv ar/.gno-
mAD: https ://gnoma d.broad insti tute.org/. dbSNP: https 
://www.ncbi.nlm.nih.gov/snp/.
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